- ReiThera has successfully manufactured and shipped approximately 700 vaccine doses to Rwanda for a clinical trial targeting Marburg virus.
- The Phase 2 trial, conducted in partnership with the Sabin Vaccine Institute, will begin with healthcare professionals at six sites in Rwanda.
ReiThera, in collaboration with the Sabin Vaccine Institute, has commenced a pivotal role in addressing the Marburg virus outbreak by manufacturing and shipping around 700 investigational vaccine doses to Rwanda. This shipment supports a Phase 2 rapid response clinical trial aimed at frontline workers, particularly healthcare professionals who are at high risk.
The clinical trial agreement has been established with the Rwanda Biomedical Centre, which will oversee the study involving approximately 700 high-risk adults. The trial will begin shortly at six clinical sites across Rwanda, focusing on healthcare providers first. The vaccine is based on the chAd3 platform and has demonstrated safety and robust immune responses in earlier Phase 1 trials.
“We were able to ship Marburg vaccine doses within 7 days of being contacted by the Rwanda government for assistance,” said Amy Finan, Chief Executive Officer of Sabin. This swift response highlights the collaborative efforts of various stakeholders in the face of a public health emergency.
ReiThera has been instrumental in producing the drug substance and managing the fill-and-finish process for the vaccine. The company emphasizes its commitment to supporting global health initiatives, particularly in response to emerging health threats like the Marburg virus.
“As we continue to combat this deadly virus, our partnership with Sabin underscores our shared goal of saving lives and ensuring equitable access to vaccines,” stated Stefano Colloca, CEO of ReiThera. The joint efforts are expected to significantly impact the global response to the Marburg virus, aiming to protect those most affected.
Overview of outsourcing trends 
